Clovis, CEO, Ex-CFO Agree to Pay $20M+ to Settle SEC Charges

Clovis Oncology, its CEO, and its former CFO have agreed to pay more than $20 million to settle federal charges that they misled investors about the efficacy of rociletinib, a lung cancer drug candidate whose clinical trials the company halted in 2016.The U.S. Securities and Exchange Commission (SEC) made its charges in a court complaint filed yesterday in U.S. District Court for the District of Colorado.The complaint alleged that Clovis misled investors soon after it announced at the American S